Pay in 4 interest-free payments of $5.71 Learn more
Ships within 48 hours · Estimated delivery Aug 4 - Aug 9
Of adults receiving combination cagrilintide and semaglutide, 71.4% lost at least 10% of their body weight and 53.6% achieved a 15% or higher weight loss at 32 weeks
Community Support and Accountability Systems Sustainable wellness often requires external support systems that provide encouragement, accountability, and shared learning opportunities
GLP-1 therapies influence pathways tied to addiction and reward, according to the Endocrine Society A randomized clinical trial published in JAMA Psychiatry found semaglutide reduced alcohol cravings and consumption Users commonly report: Reduced desire to drink Feeling full faster when drinking Less reward from alcohol The data: early, but directionally consistent While long-term industry sales data is still developing, the early signals from clinical studies, observational research, and population polling all point in the same direction: GLP-1 use is associated with lower alcohol consumption for at least some users
and this is where connected care comes to life
A probiotic with strain-level transit-time data may modestly support gut function as an adjunct
A 2024 clinical trial in chronic rhinosinusitis failed, highlighting the risks associated with indication expansion
US$ 20.90
US$ 21.23
US$ 25.41
US$ 25.89
US$ 28.84
US$ 21.98
US$ 29.39
US$ 21.48
US$ 25.58
